vs1.8

Finally Modern Science has produced this gem of a company called Modern Shots with a Punch. The company has been designing the ultimate drink against things that can invade society with wildfire abandon. Shoot it appears this invasion is rampant and continues spreading. However, their head of development Mrs. Myrna Chondria has been in research for the last several years to combat this anomoly. Her A Plus understanding of the world biosphere made her deep think. She invented a healthy solution (according to her) "This fights with a left- right knockout combo to the body". Her company's brilliant marketing campaign will prime the population to get their 2 part magical elixir and feel empowered!

Infact they grew so fast their stock quadroopled 4years ago.. Amazing! Now the whole world wants their product. Growth was magnificant a few years ago, but is it sustainable? Will people from all genres continue to use their product or is one and done? Can it keep growing at this rate or will it plateau or decline?
Its platform incorporates advances across three components, Myrna's work, delivery of it's product, and the manufacturing process, to advance its drinks. Its main products that are included in their intellectual property are known as "Spikeme "and "NEXSPIKE". Its one, two, and you will feel good, boosted, and strong!

The company C.E.O is a doctor from Switzerland (Dr. Ribo Sommes MD.) and he knows what people want to feel healthy.! He will demand a premium over and above the FMV (the Fair Market Value) Overpaying is not an option since the cost of money is expensive and interest costs have really hit hard like a sickness knocking everything out!

The price that the board of directors offers you GREAT DEAL RIGHT NOW at $20.00 per share for 400 shares (including 11 company treasury shares in addtion to the 389 common shares). ***Heck that is only $8,000.00*** . The offer is only good for today! As you ponder the tough decision Question is " Will you take it and is this a brilliancy decision or a real dumb move?

Modern Shots Annual Balance Sheet

ASSETS	**2025**	**2024**	**2023**	**2022**
Cash	--	--	--	--
Cash Equivalents	2,595	1,927	2,907	3,205
Short Term Investments	3,204	5,098	5,697	6,697
Cash & Short Term Investments	***5,799***	***7,025***	***8,604***	***9,902***
Accounts Receivable AR Net	184	358	892	1,385
Accounts Receivable Gross	368	698	1,584	1,385
Inventories - Finished Goods	33	28	24	169
Inventories -Raw Materials	29	26	15	205
Prepaid Expenses	263	307	350	851
Other Current Assets	45	58	88	65
Total Current Assets	***6,544***	***8,099***	***10,325***	***13,431***
FFE Furniture/Fixtures/Equipment,	3,590	3,482	3,091	2,797
Real Estate Buildings	1,586	950	522	460
Land and Other Parcels	78	59	22	11
Property/Plant/Equipment, Total	***2,853***	***2,955***	***2,658***	***2,139***
Depreciation	(737)	(527)	(433)	(658)
Goodwill, Net	52	52	52	52
Intangibles, Net	45	40	44	--
Long Term Investments	2,342	2,508	4,743	8,318
Notes and other Long Term Assets	341	391	604	1,970
Total Assets	***12,388***	***14,142***	***18,426***	***25,858***
LIABILITIES				
Accounts Payable AP	317	405	520	487
Accrued Expenses	1,403	1,441	1,823	2,136
Notes Payable/Short Term Debt	0	0	0	0
Capital Leases Owing	25	23	0	161
Other Current liabilities	242	337	672	2,139
Total Current Liabilities	***1,987***	***2,206***	***3,015***	***4,923***
Long Term Debt	590	--	--	--
Capital Lease Obligations	20	39	575	912
Tax incl Deferred	249	231	--	--
Other Long Term Liabilities	842	765	982	900
Total Liabilities	***3,688***	***3,241***	***4,572***	***6,735***
SHAREHOLDERS EQUITY				
Common Stock Par Value	.0394	.0386	.0382	.0385
Additional Paid-In Capital	1,382	866	371	1,173
Retained Earnings (Accumulated Deficit)	7,233	10,045	13,606	18,320
Other Equity, Total	7	(20)	(9)	(8)
Total Equity	***8,650***	***10,901***	***13,854***	***19,123***

Modern Shots ANNUAL INCOME STATEMENT

	2025	2024	2023	2022
Total Revenue (TTM)	1,944	3,236	6,848	19,263
Cost of Revenue (C.O.G.S.) TTM	577	969	2,493	5,416
Gross Profit TTM	1,378	2,267	4,355	13,487
Selling/General/Admin. Expenses TTM	1,018	1,174	1,549	1,132
Research & Developmen TTM	3,132	4,543	4,845	3,295
Depreciation/Amortization	--	--	--	--
Interest/Investment Income	--	--	--	--
Total Operating Expenses TTM	5,018	7,181	11,087	9,843
Operating Income TTM	(3074)	(3,945)	(4,239)	9420
Interest Expense - Non-Operating	(10)	(24)	(38)	(29)
Interest/Invest Income - Non-Operating	314	425	421	200
Interest Inc.(Exp.),Net-Non-Op., Total	299	345	311	151
Gain (Loss) on Sale of Assets	--	--	--	--
Other Non-Operating Income (Expense)	7	(7)	(14)	4
Net Income Before Taxes TTM	(2,768)	(3,561)	(4,714)	8,362
Provision for Income Taxe TTM	54	(46)	722	1,213
NET OPERATING INCOME (NOI) TTM	(2,822)	(3,561)	(4,714)	8,362
Preferred Dividends	--	--	--	--
Income Available to Distribute TTM	(2,822)	(3,561)	(4,714)	8,362
Average Shares Outstanding	389	384	382	416
EARNINGS PER SHARE (EPS) TTM	***(7.25)***	***(9.27)***	***(12.34)***	***20.10***

Notes, Projections, Pro Forma

This company has a huge amount of R&D (Resarch and Development) annually to get their drink out to market and approved by the F.D.A (Food and Drug Administration) Please reflect on that for creating ratios of expenses.

The Company operates various manufacturing of it's very high end drinks. The company released it's going forward guidance. This is demonstrated in a format sometimes refered to as Pro-Forma. (which is a best guess of what is expected or might be obtaainable) Keep in mind other economic factors can vary this substansially.

PRO FORMA TTM refers to Trailing Twelve Months and posted are several past annual results!

2026 Next Year earnings estimated a loss of (8.69 per share) or ($3,380.41 company wide)
The company stated that most of the expense of research and development has been paid and now the focus is on sales and reducing in house costs for a much better outlook.
The 2027 estimate of earnings is better at a loss of ($4.75) per share a dramatic improvement from 2026!
Cost of Revenue continues to decline according to the pro-forma
Selling expenses are under control and the future outlook looks fantastic!

With only a small pool of 400 shares available this appears to be an incredible opportunity.
Should you accept this offer before it is gone?